Table 4.
Twenty most rewired genes in patient iCells. For each of the 20 most rewired genes in patient iCells of infected versus control (column 1), we report the number of other studies that have reported it as a COVID-19-related gene (column 2) and if it is a differentially expressed gene (column 3). In addition, we report if it is already targeted by an FDA-approved drug (column 4) and the potential drug for re-purposing based on our framework (column 5). Finally, for each predicted DTI, we report its binding free energy (column 6) computed using AutoDock Vina v1.2 [45]. Note that we could not find a experimentally validated or predicted protein structure for RPSAP58, so we could not perform the docking for it. Additionally, we excluded from the drugs the small chemical compounds (zinc chloride, n-formylmethionine and acetylsalicylic acid).
| Gene | External Validation (#Studies) |
Diff. Exp. | Existing Drug (Drugbank) |
Potential Drug for Re-Purposing |
Binding Free Energy (kcal/mol) |
|---|---|---|---|---|---|
| ZNF35 | 8 | No | NADH | −9.8 | |
| RPSAP58 | 3 | No | NADH | - | |
| ZNF562 | 1 | No | NADH | −9.4 | |
| OLFM2 | 5 | No | FOSTAMATINIB | −9.6 | |
| CYB561 | 8 | No | ZINC CHLORIDE | - | |
| ZNF41 | 4 | No | FOSTAMATINIB | −8.5 | |
| LCMT2 | 5 | No | LEUCINE | N-FORMYLME THIONINE |
- |
| CSTF2T | 3 | No | NADH | −10.8 | |
| NUP85 | 11 | No | CLADRIBINE | −7.2 | |
| REEP4 | 9 | No | FOSTAMATINIB | −9.3 | |
| ASRGL1 | 6 | No | ASPARTIC ACID ASPARTACIAL |
NADH | -9.7 |
| ZFP62 | - | No | ARTENIMOL | −7.6 | |
| CBX5 | 10 | No | COPPER | ACETYLSALICYLIC ACID | - |
| KLHL9 | 7 | No | ARTENIMOL | −10.6 | |
| ZNF189 | 6 | No | FOSTAMATINIB | −9.9 | |
| ZNF597 | 4 | No | NADH | −10.8 | |
| H2AC20 | 7 | Yes | ARTENIMOL | −8.2 | |
| CSTF1 | 1 | No | FOSTAMATINIB | −13 | |
| ZNF507 | 9 | No | NADH | −8.6 | |
| ZNF286A | - | No | NADH | −10.7 |